Mitochondrial DNA damage by bleomycin induces AML cell death

Area of Science:

• Mitochondrial biology
• Cancer therapeutics
• Hematologic malignancies

Background:

• Mitochondria possess their own genome (mtDNA), crucial for cellular function.
• Mitochondrial dysfunction is implicated in various diseases, including cancer.
• Targeting cancer cell-specific vulnerabilities is a key therapeutic strategy.

Purpose of the Study:

• To investigate the impact of mitochondrial DNA (mtDNA) damage on acute myeloid leukemia (AML) cell function and viability.
• To identify chemotherapeutic agents capable of damaging mtDNA in AML cells.
• To evaluate bleomycin as a potential mtDNA-targeted therapy for AML.

Main Methods:

• Screening of DNA-damaging chemotherapeutic agents for mtDNA damage in AML cells.
• Assessment of mitochondrial mass and oxygen consumption following bleomycin treatment.
• Evaluation of bleomycin's efficacy in AML xenograft mouse models.
• Comparative analysis of bleomycin-induced mtDNA damage in AML cells versus normal lung tissue.

Main Results:

• Bleomycin was identified as an agent that damages mtDNA in AML cells at cytotoxic concentrations.
• Bleomycin treatment reduced mitochondrial mass and basal oxygen consumption in AML cells.
• mtDNA damage was functionally critical for bleomycin-induced AML cell death.
• Bleomycin demonstrated preferential mtDNA damage in AML cells over normal lung tissue and delayed tumor growth in vivo.

Conclusions:

• Mitochondrial DNA-targeted therapy represents a promising strategy for AML treatment.
• Bleomycin exhibits selective toxicity towards AML cells via mtDNA damage, suggesting its potential clinical utility.
• Further investigation into bleomycin's role in AML therapy is warranted.